Neurocrine/$NBIX
1D1W1MYTD1Y5YMAX
Capital at risk
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Ticker
- $NBIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.neurocrine.com
Neurocrine Metrics
BasicAdvanced
$15B
21.99
$6.82
0.39
-
Price and volume
Market cap
$15B
Beta
0.39
52-week high
$186.12
52-week low
$122.14
Average daily volume
1.1M
Financial strength
Current ratio
1.872
Quick ratio
1.46
Long term debt to equity
0.109
Total debt to equity
0.125
Interest coverage (TTM)
301.62%
Profitability
EBITDA (TTM)
904.5
Gross margin (TTM)
64.63%
Net profit margin (TTM)
20.91%
Operating margin (TTM)
25.93%
Effective tax rate (TTM)
24.96%
Revenue per employee (TTM)
$1,350,000
Management effectiveness
Return on assets (TTM)
11.82%
Return on equity (TTM)
22.09%
Valuation
Price to earnings (TTM)
21.987
Price to revenue (TTM)
4.458
Price to book
4.13
Price to tangible book (TTM)
15.76
Price to free cash flow (TTM)
17.279
Free cash flow yield (TTM)
5.79%
Free cash flow per share (TTM)
8.682
Growth
Revenue change (TTM)
34.42%
Earnings per share change (TTM)
101.21%
3-year revenue growth (CAGR)
26.34%
10-year revenue growth (CAGR)
71.87%
3-year earnings per share growth (CAGR)
57.74%
10-year earnings per share growth (CAGR)
16.93%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Analyst projections of the future price of Neurocrine stock.
Bulls say / Bears say
Total Q2 2026 revenue grew 39% year-over-year to $959 million, demonstrating robust top-line momentum. (SEC Q2 Release)
CRENESSITY net product sales reached $184 million in Q2 2026, a 247% increase from Q2 2025, underscoring strong launch momentum. (SEC Q2 Release)
Neurocrine raised full-year 2026 Ingrezza net sales guidance to $2.825–$2.875 billion, reflecting confidence in continued growth of its flagship therapy. (SEC Q2 Release)
Cash and marketable securities declined to $482 million at June 30, 2026 from $2.543 billion at December 31, 2025, indicating significant cash burn and potential liquidity pressures. (SEC Q2 Release)
Non-GAAP SG&A expenses rose to $305 million in Q2 2026, up from $255 million a year earlier, driven by expanded commercial initiatives, potentially constraining margin improvement. (SEC Q2 Release)
Ingrezza net product sales of $716 million accounted for roughly 75% of Q2 2026 revenue of $959 million, reflecting high single-product concentration risk. (SEC Q2 Release)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neurocrine News
AllArticlesVideos
Funds containing Neurocrine
AllUSDEURGBP
Fund name | Fund size | $NBIX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.19% |
iShares Healthcare Innovation£DRDR | £1B | 1.19% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.